Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Clinical Trial ID NCT00096278

PubWeight™ 17.41^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00096278

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.	J Clin Oncol	2010	4.81
2	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.	Clin Cancer Res	2009	2.23
3	Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.	Lancet Oncol	2014	1.57
4	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nat Rev Clin Oncol	2015	1.54
5	Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.	J Clin Oncol	2012	1.46
6	Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.	J Natl Cancer Inst	2011	1.12
7	New approaches in angiogenic targeting for colorectal cancer.	World J Gastroenterol	2007	1.03
8	Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.	J Natl Cancer Inst	2013	0.89
9	Predictive and prognostic markers in colorectal cancer.	Gastrointest Cancer Res	2007	0.81
10	Individualization of therapy for colorectal cancer based on clinical and molecular parameters.	Gastrointest Cancer Res	2008	0.80
11	Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.	Onco Targets Ther	2009	0.78
12	Accomplishments in 2008 in the adjuvant treatment of colon cancer.	Gastrointest Cancer Res	2009	0.77